Literature DB >> 12530011

Detection of occult breast cancer cells by amplification of CK19 mRNA by reverse transcriptase-polymerase chain reaction: role of surgical manipulation.

Maica Galán1, Nuria Viñolas, Dolors Colomer, Gemma Soler, Montserrat Muñoz, Raquel Longarón, Pere Joan Ventura, Pere Gascón, Jordi Estapé.   

Abstract

BACKGROUND: To assess if surgical manipulation increases peripheral blood cancer cells dissemination in early stage (I and II) breast cancer patients. PATIENTS AND METHODS: We analyzed 64 patients using RT-PCR for cytokeratin-19 as a marker for peripheral blood breast cancer cell dissemination. Peripheral blood was obtained at 4 different time-points (24 hours before and after surgery, one week and one month later).
RESULTS: RT-PCR was positive in 14 (24%) out of 59 evaluable patients. Circulating cells were detected in 4 out of 14 patients before surgery (7%) while in the remaining 10, the positivity was observed after surgery (17%). The percentage of patients with occult breast cancer cells increased significantly after surgery (p = 0.01).
CONCLUSION: 1) 7% of early breast cancer patients had circulating tumor cells before surgery. 2) After surgery tumor cells were detected in 17% of patients. 3) Surgery significantly increased the presence of occult breast cancer cells. 4) The clinical significance of occult breast cancer cells should be tested within a larger clinical trial trying to assess their role as an independent prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12530011

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Clinical meaning of age-related expression of fecal cytokeratin 19 in colorectal malignancy.

Authors:  Chun-Chao Chang; Shung-Haur Yang; Chih-Cheng Chien; Shu-Hung Chen; Shiann Pan; Chia-Long Lee; Chih-Ming Lin; Hsiao-Lun Sun; Chi-Cheng Huang; Yih-Yiing Wu; Ruey-Neng Yang; Chi-Jung Huang
Journal:  BMC Cancer       Date:  2009-10-22       Impact factor: 4.430

2.  Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4.

Authors:  Patricia A Cronin; Jiang H Wang; H Paul Redmond
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

3.  Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.

Authors:  Arvind K Singla; Alla Bondareva; Frank R Jirik
Journal:  Clin Exp Metastasis       Date:  2014-06-26       Impact factor: 5.150

4.  Laparoscopic surgery minimizes the surgical manipulation of isolated tumor cells leading to decreased metastasis compared to open surgery for colorectal cancer.

Authors:  Sayuri Akiyoshi; Koshi Mimori; Tomoya Sudo; Fumiaki Tanaka; Kohei Shibata; Masaki Mori
Journal:  Surg Today       Date:  2012-10-27       Impact factor: 2.549

5.  Less micrometastatic risk related to circulating tumor cells after endoscopic breast cancer surgery compared to open surgery.

Authors:  Shichao Li; Wenting Yan; Xinhua Yang; Li Chen; Linjun Fan; Haoxi Liu; Kun Liu; Yi Zhang; Jun Jiang
Journal:  BMC Cancer       Date:  2019-11-08       Impact factor: 4.430

6.  The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells.

Authors:  Alla Bondareva; Charlene M Downey; Fabio Ayres; Wei Liu; Steven K Boyd; Benedikt Hallgrimsson; Frank R Jirik
Journal:  PLoS One       Date:  2009-05-19       Impact factor: 3.240

7.  A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.

Authors:  Ruth S Weinberg; Marcelo O Grecco; Gimena S Ferro; Debora J Seigelshifer; Nancy V Perroni; Francisco J Terrier; Analía Sánchez-Luceros; Esteban Maronna; Ricardo Sánchez-Marull; Isabel Frahm; Marcelo D Guthmann; Daniela Di Leo; Eduardo Spitzer; Graciela N Ciccia; Juan Garona; Marina Pifano; Ana V Torbidoni; Daniel E Gomez; Giselle V Ripoll; Roberto E Gomez; Ignacio A Demarco; Daniel F Alonso
Journal:  Springerplus       Date:  2015-08-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.